Suppr超能文献

柯桠素对SENCAR小鼠皮肤肿瘤促进和进展的表征

Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice.

作者信息

Kruszewski F H, Conti C J, DiGiovanni J

出版信息

Cancer Res. 1987 Jul 15;47(14):3783-90.

PMID:3109733
Abstract

The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous cell carcinomas between 25 and 100 nmol/mouse. A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly. Doses of 25,100, and 220 nmol/mouse gave maximal papilloma responses of 2.90, 8.15, and 9.38 versus 0.73, 4.70, and 5.42 papillomas/mouse, respectively, in mice initiated with 25 nmol 7,12-dimethylbenz(a)anthracene. Thus, unlike 12-O-tetradecanoylphorbol-13-acetate (TPA), where a twice weekly application frequency is optimal, application of anthrone promoters such as chrysarobin once weekly is a more optimal frequency for papilloma development. Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks. Thus, groups of mice initiated with 10 nmol 7,12-dimethylbenz(a)anthracene and having promotion started in either the 3rd or the 13th week after initiation had maximal responses of 5.6 or 11.0 papillomas/mouse, respectively. In addition, the rate of papilloma development was faster in the delayed promotion group. The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. After 60 weeks of promotion, the anthrone promoter-treated groups had carcinoma:papilloma ratios 2.5 to 5.0 times higher than the TPA-treated groups. This was due primarily to the fact that similar carcinoma responses were observed in both anthrone- and TPA-treated mice at optimal promoting doses whereas the papilloma responses were significantly lower in the former groups. The data suggest that anthrone derivatives are very efficient tumor promoters. The results are further discussed in terms of mechanisms of skin tumor promotion.

摘要

在SENCAR小鼠中,对蒽酮衍生物促进皮肤肿瘤反应的特性进行了进一步研究。柯桠素(1,8 - 二羟基 - 3 - 甲基 - 9 - 蒽酮)是一种有效的皮肤肿瘤促进剂,每周给药两次时,剂量在25至100 nmol/小鼠之间,乳头状瘤和鳞状细胞癌的发生率呈剂量依赖性增加。当柯桠素每周给药一次时,观察到乳头状瘤和癌形成的类似剂量反应关系。有趣的是,柯桠素每周给药一次时作为皮肤肿瘤促进剂的活性约为每周给药两次时的两倍。在以25 nmol 7,12 - 二甲基苯并(a)蒽启动的小鼠中,25、100和220 nmol/小鼠的剂量分别产生了2.90、8.15和9.38个乳头状瘤的最大反应,而每只小鼠分别为0.73、4.70和5.42个乳头状瘤。因此,与12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)不同,TPA每周给药两次是最佳频率,而蒽酮促进剂如柯桠素每周给药一次是乳头状瘤发展的更优频率。当促进开始延迟额外10周时,柯桠素也是一种更有效的皮肤肿瘤促进剂。因此,以10 nmol 7,12 - 二甲基苯并(a)蒽启动且在启动后第3周或第13周开始促进的小鼠组,每只小鼠的最大反应分别为5.6个或11.0个乳头状瘤。此外延迟促进组中乳头状瘤的发展速度更快。在所有用柯桠素处理的组中检查了乳头状瘤向癌的进展,并与三组用3.4 nmol TPA处理的小鼠进行了比较。促进60周后,蒽酮促进剂处理组的癌与乳头状瘤的比率比TPA处理组高2.5至5.0倍。这主要是由于在最佳促进剂量下,蒽酮处理组和TPA处理组的小鼠中观察到类似的癌反应,而前一组中的乳头状瘤反应明显较低。数据表明蒽酮衍生物是非常有效的肿瘤促进剂。将根据皮肤肿瘤促进机制进一步讨论这些结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验